TriSalus Life Sciences Strengthens Board with Healthcare Experts
Portfolio - People | Feb 04, 2025 | Tullis-Dickerson & Co Inc
TriSalus Life Sciences, a Nasdaq-listed biomedical technology firm, has bolstered its Board of Directors with the addition of William Valle and Dr. Gary Gordon. Valle, with extensive experience in medical device commercialization from Fresenius, and Gordon, an oncology expert from AbbVie, are set to enhance TriSalus' strategic direction. Their expertise aligns with TriSalus' mission to improve therapy delivery for solid tumors using Pressure-Enabled Drug Delivery (PEDD) technology and the investigational immunotherapy nelitolimod. Valle and Gordon's appointments are part of TriSalus' strategic efforts to innovate in the oncology field, particularly in addressing pancreatic cancer treatment challenges.
Sectors
- Healthcare
- Medical Devices
- Pharmaceuticals
Geography
- United States – TriSalus Life Sciences and the new board members have significant operations and influence in the U.S. healthcare market.
Industry
- Healthcare – The article focuses on TriSalus Life Sciences, which operates in the healthcare sector, specifically in biomedical technology and oncology.
- Medical Devices – William Valle brings significant experience in medical device commercialization, relevant to TriSalus' use of innovative drug delivery systems.
- Pharmaceuticals – The involvement of Dr. Gary Gordon highlights the pharmaceutical aspect, particularly in drug development and oncology.
Financials
- – No specific financial information such as deal price or enterprise value is mentioned in the article.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| TriSalus Life Sciences Inc. | Target Company | Company | A biomedical technology company focused on improving therapy delivery for solid tumors. |
| William Valle | Board Member | Person | Former Fresenius executive with expertise in medical device commercialization. |
| Gary B. Gordon, MD, PhD | Board Member | Person | An accomplished pharmaceutical executive with a background in oncology drug development. |
| Tullis-Dickerson & Co Inc. | Private Equity Firm | Company | The private equity firm associated with TriSalus Life Sciences. |